Kindred Biosciences Stock Price, News & Analysis (NASDAQ:KIN)

$7.35 0.00 (0.00 %)
(As of 11/20/2017 04:12 AM ET)
Previous Close$7.35
Today's Range$7.27 - $7.50
52-Week Range$3.90 - $9.65
Volume58,100 shs
Average Volume147,902 shs
Market Capitalization$206.96 million
P/E RatioN/A
Dividend YieldN/A
Beta0.16

About Kindred Biosciences (NASDAQ:KIN)

Kindred Biosciences logoKindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:KIN
  • CUSIP: N/A
  • Web: www.kindredbio.com
Debt:
  • Current Ratio: 24.02%
  • Quick Ratio: 24.02%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $2.90 per share
  • Price / Book: 2.53
Profitability:
  • Trailing EPS: ($1.17)
  • Net Income: ($22,490,000.00)
  • Return on Equity: -36.18%
  • Return on Assets: -34.66%
Misc:
  • Employees: 41
  • Outstanding Shares: 28,160,000
 

Frequently Asked Questions for Kindred Biosciences (NASDAQ:KIN)

What is Kindred Biosciences' stock symbol?

Kindred Biosciences trades on the NASDAQ under the ticker symbol "KIN."

How were Kindred Biosciences' earnings last quarter?

Kindred Biosciences, Inc. (NASDAQ:KIN) released its quarterly earnings data on Tuesday, November, 7th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.04. View Kindred Biosciences' Earnings History.

Where is Kindred Biosciences' stock going? Where will Kindred Biosciences' stock price be in 2017?

5 Wall Street analysts have issued 12-month price targets for Kindred Biosciences' shares. Their predictions range from $8.00 to $10.50. On average, they anticipate Kindred Biosciences' share price to reach $9.50 in the next year. View Analyst Ratings for Kindred Biosciences.

Who are some of Kindred Biosciences' key competitors?

Who are Kindred Biosciences' key executives?

Kindred Biosciences' management team includes the folowing people:

  • Wendy Wee, Chief Financial Officer (Age 64)
  • Denise M. Bevers, Chief Operating Officer, Secretary (Age 47)
  • Stephen Sundlof Ph.D., Executive Vice President - Regulatory Affairs and Quality, Chief Scientific Officer (Age 63)
  • Herbert D. Montgomery, Independent Director (Age 68)
  • Raymond Townsend, Independent Director (Age 70)
  • Ervin Veszpremi, Independent Director (Age 56)

Who owns Kindred Biosciences stock?

Kindred Biosciences' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Dimensional Fund Advisors LP (4.82%), General American Investors Co. Inc. (2.39%), Wells Fargo & Company MN (1.20%), New York State Common Retirement Fund (0.95%), Pacific Grove Capital LP (0.67%) and Granite Investment Partners LLC (0.33%). Company insiders that own Kindred Biosciences stock include Ernest Mario, Park West Asset Management Llc, Raymond Townsend and Richard Chin. View Institutional Ownership Trends for Kindred Biosciences.

Who sold Kindred Biosciences stock? Who is selling Kindred Biosciences stock?

Kindred Biosciences' stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC and Dimensional Fund Advisors LP. Company insiders that have sold Kindred Biosciences company stock in the last year include Park West Asset Management Llc and Richard Chin. View Insider Buying and Selling for Kindred Biosciences.

Who bought Kindred Biosciences stock? Who is buying Kindred Biosciences stock?

Kindred Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including General American Investors Co. Inc., Pacific Grove Capital LP, New York State Common Retirement Fund, Granahan Investment Management Inc. MA, SG Americas Securities LLC, Trexquant Investment LP, Bank of New York Mellon Corp and Prudential Financial Inc.. Company insiders that have bought Kindred Biosciences stock in the last two years include Ernest Mario, Park West Asset Management Llc and Raymond Townsend. View Insider Buying and Selling for Kindred Biosciences.

How do I buy Kindred Biosciences stock?

Shares of Kindred Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Kindred Biosciences' stock price today?

One share of Kindred Biosciences stock can currently be purchased for approximately $7.35.

How big of a company is Kindred Biosciences?

Kindred Biosciences has a market capitalization of $206.96 million. The biopharmaceutical company earns ($22,490,000.00) in net income (profit) each year or ($1.17) on an earnings per share basis. Kindred Biosciences employs 41 workers across the globe.

How can I contact Kindred Biosciences?

Kindred Biosciences' mailing address is 1555 BAYSHORE HIGHWAY SUITE 200, BURLINGAME CA, 94010. The biopharmaceutical company can be reached via phone at 650-701-7901 or via email at [email protected]


MarketBeat Community Rating for Kindred Biosciences (NASDAQ KIN)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  242
MarketBeat's community ratings are surveys of what our community members think about Kindred Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Kindred Biosciences (NASDAQ:KIN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 1 Hold Rating, 3 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $9.50 (29.25% upside)

Consensus Price Target History for Kindred Biosciences (NASDAQ:KIN)

Price Target History for Kindred Biosciences (NASDAQ:KIN)

Analysts' Ratings History for Kindred Biosciences (NASDAQ:KIN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/17/2017HC WainwrightInitiated CoverageBuy -> Buy$9.50N/AView Rating Details
6/16/2017AegisInitiated CoverageBuy$10.50HighView Rating Details
5/31/2017FBR & CoReiterated RatingBuyLowView Rating Details
5/15/2017BMO Capital MarketsReiterated RatingHold$8.00N/AView Rating Details
1/3/2017Feltl & Co.Reiterated RatingStrong-BuyN/AView Rating Details
11/1/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$7.50N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Kindred Biosciences (NASDAQ:KIN)

Earnings by Quarter for Kindred Biosciences (NASDAQ:KIN)

Earnings History by Quarter for Kindred Biosciences (NASDAQ KIN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017Q3 2017($0.33)($0.29)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.33)($0.29)ViewListenView Earnings Details
5/4/2017Q1 2017($0.34)($0.30)ViewListenView Earnings Details
3/1/2017Q416($0.36)($0.29)ViewListenView Earnings Details
11/7/2016Q316($0.36)($0.29)ViewListenView Earnings Details
8/8/2016Q216($0.32)($0.25)ViewN/AView Earnings Details
3/2/2016Q415($0.44)($0.32)ViewN/AView Earnings Details
11/9/2015Q3 2015($0.44)($0.36)ViewN/AView Earnings Details
8/10/2015Q2($0.42)($0.35)ViewN/AView Earnings Details
5/8/2015Q115($0.40)($0.34)ViewN/AView Earnings Details
3/12/2015Q414($0.40)($0.34)ViewN/AView Earnings Details
11/13/2014Q3 2014($0.43)($0.31)ViewN/AView Earnings Details
8/13/2014Q2 2014($0.35)($0.42)ViewN/AView Earnings Details
5/12/2014Q1 14($0.18)($0.38)ViewN/AView Earnings Details
3/6/2014($0.21)($0.40)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Kindred Biosciences (NASDAQ:KIN)
Current Year EPS Consensus Estimate: $-1.14 EPS
Next Year EPS Consensus Estimate: $-1.09 EPS

Dividends

Dividend History for Kindred Biosciences (NASDAQ:KIN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Kindred Biosciences (NASDAQ KIN)

Insider Ownership Percentage: 19.10%
Institutional Ownership Percentage: 61.77%
Insider Trades by Quarter for Kindred Biosciences (NASDAQ:KIN)
Institutional Ownership by Quarter for Kindred Biosciences (NASDAQ:KIN)

Insider Trades by Quarter for Kindred Biosciences (NASDAQ KIN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/12/2017Park West Asset Management LlcMajor ShareholderBuy600,000$7.50$4,500,000.00View SEC Filing  
7/3/2017Richard ChinInsiderSell13,000$8.26$107,380.00View SEC Filing  
6/22/2017Richard ChinInsiderSell13,000$7.75$100,750.00View SEC Filing  
6/8/2017Park West Asset Management LlcMajor ShareholderBuy15,311$6.65$101,818.15View SEC Filing  
5/11/2017Park West Asset Management LlcMajor ShareholderBuy155,076$6.83$1,059,169.08View SEC Filing  
3/15/2017Park West Asset Management LlcMajor ShareholderBuy400,000$6.60$2,640,000.00View SEC Filing  
3/13/2017Park West Asset Management LlcMajor ShareholderBuy4,200$6.20$26,040.00View SEC Filing  
3/9/2017Park West Asset Management LlcMajor ShareholderBuy18,066$6.08$109,841.28View SEC Filing  
1/13/2017Park West Asset Management LlcMajor ShareholderBuy1,690,000$6.20$10,478,000.00View SEC Filing  
1/9/2017Park West Asset Management LlcMajor ShareholderBuy131,500$5.30$696,950.00View SEC Filing  
1/6/2017Park West Asset Management LlcMajor ShareholderBuy110,617$5.10$564,146.70View SEC Filing  
12/16/2016Park West Asset Management LlcInsiderSell18,000$4.78$86,040.00View SEC Filing  
12/14/2016Park West Asset Management LlcMajor ShareholderBuy8,334$4.75$39,586.50View SEC Filing  
12/13/2016Park West Asset Management LlcMajor ShareholderBuy1,148$4.75$5,453.00View SEC Filing  
12/12/2016Park West Asset Management LlcMajor ShareholderBuy3,112$4.74$14,750.88View SEC Filing  
3/15/2016Ernest MarioDirectorBuy30,000$3.55$106,500.00View SEC Filing  
11/23/2015Raymond TownsendDirectorBuy2,000$4.00$8,000.00View SEC Filing  
11/18/2015Raymond TownsendDirectorBuy2,323$4.78$11,103.94View SEC Filing  
8/31/2015Raymond TownsendDirectorBuy1,677$5.85$9,810.45View SEC Filing  
8/14/2015Raymond TownsendDirectorBuy3,000$6.04$18,120.00View SEC Filing  
9/29/2014Oleg NodelmanDirectorBuy100,000$9.56$956,000.00View SEC Filing  
9/3/2014Ernest MarioDirectorBuy10,000$10.55$105,500.00View SEC Filing  
8/28/2014Oleg NodelmanDirectorBuy47,000$10.85$509,950.00View SEC Filing  
8/26/2014Oleg NodelmanDirectorBuy85,244$10.50$895,062.00View SEC Filing  
12/12/2013Kevin SchultzInsiderBuy4,000$7.00$28,000.00View SEC Filing  
12/12/2013Oleg NodelmanDirectorBuy400,000$7.00$2,800,000.00View SEC Filing  
12/12/2013Stephen SundlofSVPBuy1,000$7.00$7,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Kindred Biosciences (NASDAQ KIN)

Source:
DateHeadline
Kindred Biosciences, Inc. (KIN) Coverage Initiated by Analysts at HC WainwrightKindred Biosciences, Inc. (KIN) Coverage Initiated by Analysts at HC Wainwright
www.americanbankingnews.com - November 18 at 11:38 AM
Kindred Biosciences, Inc. (KIN) Given Consensus Rating of "Buy" by AnalystsKindred Biosciences, Inc. (KIN) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - November 16 at 7:50 PM
Edited Transcript of KIN earnings conference call or presentation 7-Nov-17 9:30pm GMTEdited Transcript of KIN earnings conference call or presentation 7-Nov-17 9:30pm GMT
finance.yahoo.com - November 13 at 11:02 AM
Kindred Biosciences, Inc. (KIN) Issues Quarterly  Earnings ResultsKindred Biosciences, Inc. (KIN) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 8 at 7:11 PM
Kindred Biosciences Announces Third Quarter 2017 Financial ResultsKindred Biosciences Announces Third Quarter 2017 Financial Results
www.bizjournals.com - November 8 at 11:27 AM
Kindred Biosciences, Inc. (KIN) Expected to Announce Earnings of -$0.33 Per ShareKindred Biosciences, Inc. (KIN) Expected to Announce Earnings of -$0.33 Per Share
www.americanbankingnews.com - November 4 at 5:24 PM
Kindred Biosciences, Inc. (KIN) Set to Announce Earnings on TuesdayKindred Biosciences, Inc. (KIN) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 31 at 11:58 AM
Kindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from BrokeragesKindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 22 at 8:38 PM
Kindred Biosciences to Announce Third Quarter 2017 Financial ResultsKindred Biosciences to Announce Third Quarter 2017 Financial Results
finance.yahoo.com - October 11 at 5:05 PM
Contrasting Kindred Biosciences (KIN) & Pain Therapeutics (PTIE)Contrasting Kindred Biosciences (KIN) & Pain Therapeutics (PTIE)
www.americanbankingnews.com - October 6 at 4:10 PM
Kindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals ConferenceKindred Biosciences to Participate in the Oppenheimer & Co. Specialty Pharmaceuticals Conference
finance.yahoo.com - October 6 at 2:37 AM
Head-To-Head Analysis: Spark Therapeutics (ONCE) & Kindred Biosciences (KIN)Head-To-Head Analysis: Spark Therapeutics (ONCE) & Kindred Biosciences (KIN)
www.americanbankingnews.com - October 1 at 2:32 AM
Kindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from AnalystsKindred Biosciences, Inc. (KIN) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 27 at 8:44 PM
Kindred Biosciences (KIN) Presents At Ladenburg Thalmann 2017 Healthcare Conference - SlideshowKindred Biosciences (KIN) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
seekingalpha.com - September 27 at 4:17 PM
Comparing Kindred Biosciences (KIN) and Its PeersComparing Kindred Biosciences (KIN) and Its Peers
www.americanbankingnews.com - September 20 at 8:08 AM
Kindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. SundlofKindred Biosciences Announces Plans for Promotion of Dr. Zhan and Retirement of Dr. Sundlof
finance.yahoo.com - September 11 at 9:35 PM
Kindred Biosciences, Inc. (KIN) Given Average Rating of "Buy" by AnalystsKindred Biosciences, Inc. (KIN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - September 2 at 8:46 PM
Kindred Biosciences to Present at Upcoming Investor ConferencesKindred Biosciences to Present at Upcoming Investor Conferences
finance.yahoo.com - August 31 at 6:40 AM
Kindred Biosciences, Inc. (KIN) Short Interest Down 29.0% in JulyKindred Biosciences, Inc. (KIN) Short Interest Down 29.0% in July
www.americanbankingnews.com - August 14 at 3:04 AM
Kindred Biosciences, Inc. (NASDAQ:KIN) Releases Quarterly  Earnings ResultsKindred Biosciences, Inc. (NASDAQ:KIN) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 8 at 11:14 AM
Edited Transcript of KIN earnings conference call or presentation 7-Aug-17 8:30pm GMTEdited Transcript of KIN earnings conference call or presentation 7-Aug-17 8:30pm GMT
finance.yahoo.com - August 8 at 5:40 AM
Kindred Biosciences Announces Second Quarter 2017 Financial ResultsKindred Biosciences Announces Second Quarter 2017 Financial Results
finance.yahoo.com - August 7 at 7:38 PM
Kindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners MeetingKindred Biosciences Sponsors Veterinary Students to Attend the 2017 American Association of Feline Practitioners Meeting
finance.yahoo.com - August 4 at 11:59 PM
 Brokerages Anticipate Kindred Biosciences, Inc. (KIN) Will Post Earnings of -$0.29 Per Share Brokerages Anticipate Kindred Biosciences, Inc. (KIN) Will Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - August 2 at 10:14 PM
Kindred Biosciences, Inc. (KIN) Short Interest UpdateKindred Biosciences, Inc. (KIN) Short Interest Update
www.americanbankingnews.com - July 29 at 7:15 AM
BRIEF-Kindred Biosciences says board appointed Wendy Wee as CFO - SEC FilingBRIEF-Kindred Biosciences says board appointed Wendy Wee as CFO - SEC Filing
www.reuters.com - July 29 at 1:09 AM
Kindred Biosciences to Announce Second Quarter 2017 Financial ResultsKindred Biosciences to Announce Second Quarter 2017 Financial Results
finance.yahoo.com - July 24 at 10:19 AM
Kindred Biosciences, Inc. (NASDAQ:KIN) Receives Average Rating of "Buy" from BrokeragesKindred Biosciences, Inc. (NASDAQ:KIN) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 14 at 10:52 PM
Park West Asset Management Llc Purchases 600,000 Shares of Kindred Biosciences, Inc. (KIN) StockPark West Asset Management Llc Purchases 600,000 Shares of Kindred Biosciences, Inc. (KIN) Stock
www.americanbankingnews.com - July 14 at 7:59 PM
KindredBio Announces Pricing of Public OfferingKindredBio Announces Pricing of Public Offering
finance.yahoo.com - July 13 at 6:07 AM
BRIEF-Kindredbio announces proposed public offering of common stockBRIEF-Kindredbio announces proposed public offering of common stock
www.reuters.com - July 12 at 1:51 AM
KindredBio Announces Proposed Public Offering of Common StockKindredBio Announces Proposed Public Offering of Common Stock
finance.yahoo.com - July 12 at 1:51 AM
Kindred Biosciences, Inc. (NASDAQ:KIN) Expected to Post Earnings of -$0.29 Per ShareKindred Biosciences, Inc. (NASDAQ:KIN) Expected to Post Earnings of -$0.29 Per Share
www.americanbankingnews.com - July 11 at 2:28 PM
Former Boehringer Ingelheim manufacturing plant finds new ownerFormer Boehringer Ingelheim manufacturing plant finds new owner
www.bizjournals.com - July 7 at 6:46 AM
Richard Chin Sells 13,000 Shares of Kindred Biosciences, Inc. (KIN) StockRichard Chin Sells 13,000 Shares of Kindred Biosciences, Inc. (KIN) Stock
www.americanbankingnews.com - July 6 at 8:06 PM
Kindred Biosciences (KIN) Buys Kansas Manufacturing Plant and Reports Execution of Commercial Manufacturing Agreement for ZimetaKindred Biosciences (KIN) Buys Kansas Manufacturing Plant and Reports Execution of Commercial Manufacturing Agreement for Zimeta
www.streetinsider.com - June 26 at 8:03 PM
BRIEF-Kindred Biosciences reports acquisition of Kansas manufacturing plantBRIEF-Kindred Biosciences reports acquisition of Kansas manufacturing plant
www.reuters.com - June 26 at 8:03 PM
BRIEF-Kindred Biosciences announces Q1 loss per share $0.30BRIEF-Kindred Biosciences announces Q1 loss per share $0.30
www.reuters.com - May 4 at 1:16 AM
Kindred Biosciences, Inc. 2017 Q1 - Results - Earnings Call SlidesKindred Biosciences, Inc. 2017 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 4 at 1:16 AM
Q4 2016 Kindred Biosciences Inc Earnings Release - After Market CloseQ4 2016 Kindred Biosciences Inc Earnings Release - After Market Close
biz.yahoo.com - March 1 at 11:27 AM
Kindred Biosciences (KIN) Receives Technical Section Complete Letter for Effectiveness from FDA for Mirataz New Animal Drug ApplicationKindred Biosciences (KIN) Receives Technical Section Complete Letter for Effectiveness from FDA for Mirataz New Animal Drug Application
www.streetinsider.com - February 6 at 11:19 PM
BRIEF-Kindred Biosciences receives early approval of effectiveness technical section from FDA for MiratazBRIEF-Kindred Biosciences receives early approval of effectiveness technical section from FDA for Mirataz
www.reuters.com - February 6 at 6:17 PM
9:00 am Kindred Biosciences receives early approval of effectiveness technical section from the FDA for Mirataz new animal drug application (shares halted)9:00 am Kindred Biosciences receives early approval of effectiveness technical section from the FDA for Mirataz new animal drug application (shares halted)
us.rd.yahoo.com - February 6 at 10:21 AM
Kindred Biosciences (KIN) Looks Good: Stock Jumps 9.5%Kindred Biosciences (KIN) Looks Good: Stock Jumps 9.5%
www.zacks.com - January 16 at 8:35 AM
KindredBio: An Undervalued, Under-Followed, Low-Float Play On The Humanization Of PetsKindredBio: An Undervalued, Under-Followed, Low-Float Play On The Humanization Of Pets
seekingalpha.com - January 14 at 12:26 AM
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive AgreementKINDRED BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
biz.yahoo.com - December 20 at 11:45 AM
KINDRED BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and ExhibitsKINDRED BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - December 7 at 6:14 PM
BRIEF-Kindred Biosciences to present Zimeta pivotal data at Annual American Association of Equine Practitioners ConventionBRIEF-Kindred Biosciences to present Zimeta pivotal data at Annual American Association of Equine Practitioners Convention
www.reuters.com - November 29 at 4:18 PM
Tracking Seth Klarmans Baupost Group Holdings - Q3 2016 UpdateTracking Seth Klarman's Baupost Group Holdings - Q3 2016 Update
seekingalpha.com - November 16 at 9:29 AM
Kindred Biosciences Announces Third Quarter 2016 Financial ResultsKindred Biosciences Announces Third Quarter 2016 Financial Results
www.prnewswire.com - November 7 at 9:38 AM

Social Media

Financials

Chart

Kindred Biosciences (NASDAQ KIN) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.